Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 4, 2009, Pages 552-558

  Schmid, P ^a   Brodmann, D ^b   Fischer, A G ^b   Wuillemin, Walter A ^a,c  

^a Division of Hematology and Central Hematology Laboratory   (Switzerland)

^b Division of Nephrology   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Dalteparin; Low molecular weight heparin; Pharmacokinetics; Prophylaxis; Renal insufficiency

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DALTEPARIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; COHORT STUDIES; DALTEPARIN; DRUG TOXICITY; FACTOR XA; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PREMEDICATION; THROMBOEMBOLISM;

EID: 63049127820     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03292.x     Document Type: Article

References (32)

1. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 141S-59S.
2. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
3. Wuillemin WA, Wirz P, Welte S, Dörffler-Melly J, Bounameaux H. Prophylaxe venöser Thromboembolien - Beispiele für Praxisempfehlungen. Schweiz Med Forum 2007; 7: 198-204.
4. Chopard P, Dörffler-Melly J, Hess U, Wuillemin WA, Hayoz D, Gallino A, Bachli EB, Canova CR, Isenegger J, Rubino R, Bounameaux H. Venous thromboembolism prophylaxis in acutely ill medical patients: Definite need for improvement. J.Intern Med 2005; 257: 352-7.
5. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673-84.
6. Schmid P, Fischer AG, Wuillemin WA. Prevalence of impaired renal function in medical inpatients. Swiss Med Wkly 2007; 137: 514.
7. Sohal AS, Gangji AS, Crowther MA, Treleaven D. Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res 2006; 118: 417-22.
8. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793-800.
9. Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004; 110: 392-8.
10. Collet JP, Montalescot G, Choussat R, Lison L, Ankri A. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol 2001; 80: 81-2.
11. Kruse MW, Lee JJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J 2004; 148: 582-9.
12. Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4days in patients with renal impairment. Thromb Res 2002; 105: 225-31.
13. Frydman A. Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996; 26(Suppl 2): 24-38.
14. Palm M, Mattsson C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 1987; 58: 932-5.
15. Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, Thebault JJ. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995; 73: 630-40.
16. Shprecher AR, Cheng-Lai A, Madsen EM, Cohen HW, Sinnett MJ, Wong ST, Billett HH. Peak antifactor Xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. Pharmacotherapy 2005; 25: 817-22.
17. Simoneau G, Bergmann JF, Kher A, Soria C, Tobelem G. Pharmacokinetics of a low molecular weight heparin [Fragmin(R)] in young and elderly subjects. Thromb Res 1992; 66: 603-7.
18. Rabbat CG, Cook DJ, Crowther MA, McDonald E, Clarke F, Meade MO, Lee KA, Cook RJ. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J.Crit Care 2005; 20: 357-63.
19. Tincani E, Mannucci C, Casolari B, Turrini F, Crowther MA, Prisco D, Cenci AM, Bondi M. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: A pilot study. Haematologica 2006; 91: 976-9.
20. Stöbe J, Siegemund A, Achenbach H, Preiss C, Preiss R. Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency. Int J Clin Pharmacol Ther 2006; 44: 455-65.
21. Arbogast HP, Göhring P, Jauch K-W. Thromboembolieprophylaxe in der Transplantationschirurgie. Vascular Care 2007; 12: 32-9.
22. Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y, Albert M, Granton J, Hebert P, Pagliarello G, Marshall J, Fowler R, Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D, Crowther M. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: An assessment of safety and Tharmacodynamics: the DIRECT study. Arch Intern Med 2008; 168: 1805-12.
23. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, Nielsen JD, Horn A, Mohn AC, Somod L, Olsen B. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: A multicenter randomized open-label study. J.Thromb Haemost 2006; 4: 2384-90.
24. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Turpie AGG, Yusen RD. Late breaking clinical trial: Extended-duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced mobility: The EXCLAIM study. J Thromb Haemost 2007; 5(Suppl. 2): O-S-001.
25. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-47.
26. Heizmann M, Baerlocher GM, Steinmann F, Horber FF, Wuillemin WA. Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis. Thromb Res 2002; 106: 179-81.
27. Hulot JS, Vantelon C, Urien S, Bouzamondo A, MahéI, Ankri A, Montalescot G, Lechat P. Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. Ther Drug Monit 2004; 26: 305-10.
28. Keller F, Giehl M, Frankewitsch T, Zellner D. Pharmacokinetics and drug dosage adjustment to renal impairment. Nephrol Dial Transplant 1995; 10: 1516-20.
29. Dörffler-Melly J, de Jonge E, de Pont AC, Meijers J, Vroom MB, Buller HR, Levi M. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002; 359: 849-50.
30. Brophy DF, Martin EJ, Best AM, Gehr TW, Carr ME. Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction. J.Thromb Haemost 2004; 2: 1299-304.
31. Al Dieri R, Alban S, Beguin S, Hemker HC. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J.Thromb Haemost 2006; 4: 83-9.
32. Hemker HC, Al Dieri R, Beguin S. Laboratory monitoring of low-molecular-weight heparin therapy - part II. Monitoring LMWH therapy? For the moment a non-question. J.Thromb Haemost 2005; 3: 571-3.